77.30MMarket Cap-2254P/E (TTM)
3.920High3.510Low188.01KVolume3.770Open3.780Pre Close691.53KTurnover1.08%Turnover RatioLossP/E (Static)21.84MShares5.99052wk High-13.41P/B61.62MFloat Cap0.82052wk Low--Dividend TTM17.41MShs Float9.640Historical High--Div YieldTTM10.85%Amplitude0.820Historical Low3.678Avg Price1Lot Size
MAIA Biotechnology Stock Forum
1 MINUTE AGO, 8:41 AM EDT
VIA BUSINESSWIRE
MAIA Biotechnology Reveals New Clinical Data Showing THIO’s Strong Efficacy in Non-Small Cell Lung Cancer
MAIA Biotechnology announced new data from its Phase 2 THIO-101 clinical trial, showing promising results for the drug THIO when combined with cemiplimab (Libtayo®) in advanced non-small cell lung cancer (NSCLC) patients who have failed 2 or more standard-of-care therapies. The trial reports a favorable overall response rate (ORR) of 38% and a disease contro...
$Iovance Biotherapeutics(IOVA.US)$ Phase 2
$Supernus Pharmaceuticals(SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF(BINV.US)$ Phase 2a
$MorphoSys(MOR.US)$ Phase 2
$Nuvation Bio(NUVB.US)$ Phase 2
$ALX Oncology(ALXO.US)$ Phase 2
$BioXcel Therapeutics(BTAI.US)$ Phase 2
$Purple Biotech(PPBT.US)$ Phase 2
$Arcus Biosciences(RCUS.US)$ Phase 2
$Medicenna Therapeutics(MDNAF.US)$ Phase 2b
$Affimed NV(AFMD.US)$ Phase 2
$Barinthus Biotherapeutics(BRNS.US)$ Phase 2b...
No comment yet